Bet_Noire
Relmada Therapeutics (NASDAQ:RLMD) shares finished Monday’s session 5% higher after the company reported it would no longer pursue two Phase 3 studies for its drug REL-1017 and was exploring strategic options.
The drug developer said that after evaluating the full